权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel mechanism of action as therapeutic strategy for optic neuritis

作为视神经炎治疗策略的新作用机制

基本信息

批准号：
8511676
负责人：
Peter Koulen
金额：
$ 35.63万
依托单位：
UNIVERSITY OF MISSOURI KANSAS CITY
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-08-01 至 2015-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8511676
关键词：
Acute Address Affect Aftercare Animal Model Autoimmune Process Autoimmunity Axon Behavioral Biological Biological Preservation Biological Products Blindness Brain CNS autoimmune disease CNS autoimmunity CNS degeneration Cell physiology Cells Characteristics Clinical Clinical Trials Combined Modality Therapy Complement Complex Complication Confocal Microscopy Cytophotometry Data Degenerative Disorder Detection Development Diagnosis Diagnostic Differential Diagnosis Disease Disease Progression Disease model Dose Drug Combinations Event Experimental Models Eye Generic Drugs Genomics Goals Healthcare Heat shock proteins Human Human Pathology Immunoblot Analysis In Vitro Inflammation Inflammatory Interdisciplinary Study Intervention Knowledge Measures Mediating Methods Minority Modeling Multiple Sclerosis Myelin Myelin Proteins Natural regeneration Nerve Nerve Degeneration Neurons Optic Nerve Optic Neuritis Pathologic Pathology Pathway interactions Patients Pattern Performance Pharmaceutical Preparations Phase Phenotype Population Preclinical Testing Prevention Process Productivity Quality of life Rattus Regimen Research Research Project Grants Resveratrol Retina Rodent Model Sequential Treatment Signal Transduction Staging Structure Testing Therapeutic Therapeutic Intervention Toxic effect Treatment Efficacy Treatment Protocols United States Vision Visual Acuity Visual impairment autoimmune optic neuritis axon regeneration axonal degeneration base care burden clinical phenotype clinically relevant disease phenotype drug development functional disability functional outcomes geranylgeranylacetone health care delivery human disease immunoreactivity improved in vivo inhibitor/antagonist innovation neuron loss neuroprotection novel novel therapeutics optic nerve regeneration physical conditioning prenylation prevent regenerative remyelination repaired research study small molecule therapy design therapy development trans-resveratrol treatment strategy

项目摘要

DESCRIPTION (provided by applicant): Degeneration or damage of the optic nerve and the retina due to optic neuritis is a leading cause of visual loss and blindness in the United States and worldwide associated with multiple sclerosis and autoimmune damage to the CNS. The proposed multidisciplinary research project will focus on the development and characterization of a novel pharmacological intervention strategy that combines drugs to control structural and functional degeneration in autoimmune optic neuritis. Suppression of CNS inflammation, prevention of loss and damage of myelinated axons, and stimulation of regeneration and remyelination of damaged axons are the primary goals of the study. To this end, preclinical testing of the new therapeutic strategy will be performed in established models of human autoimmune optic neuritis. These experiments will determine efficacy of treatment in terminating and/or preventing autoimmune optic neuritis associated neuronal loss and preservation of visual function, and to generate data to support feasibility for and move positive findings to phase 1 or 2 clinical trials. Specifically, we will test the hypothesis that the proposed treatment strategy cn target and remedy specific phenotypes that include combinations of separate pathologies encountered during distinct stages of optic neuritis and multiple sclerosis, leading to improvement of visual impairment and functional deficits associated with the disease. The determination of neuronal viability and the acquired knowledge on associated therapeutic parameters will indicate the potential of the method to remedy autoimmune optic neuritis as the overall goal of the project. This therapy approach for autoimmune optic neuritis focuses on suppression of CNS autoimmunoreactivity, neuroprotection, axon regeneration and remyelination via different mechanisms. It has the potential to be both preventative and therapeutic and to complement existing treatment designs and rationales addressing other aspects of autoimmune optic neuritis treatment.

描述（由申请人提供）：视神经炎引起的视神经和视网膜变性或损伤是美国和世界范围内视力丧失和失明的主要原因，与多发性硬化症和CNS自身免疫损伤相关。拟议的多学科研究项目将侧重于开发和表征一种新的药理学干预策略，结合药物来控制自身免疫性视神经炎的结构和功能变性。抑制CNS炎症、预防有髓鞘轴突的损失和损伤以及刺激受损轴突的再生和髓鞘再生是本研究的主要目标。为此，将在已建立的人类自身免疫性视神经炎模型中进行新治疗策略的临床前测试。这些实验将确定治疗在终止和/或预防自身免疫性视神经炎相关神经元损失和视觉功能保留方面的功效，并生成数据以支持可行性并将阳性结果转移到1期或2期临床试验。具体来说，我们将测试的假设，提出的治疗策略cn目标和补救特定的表型，包括在不同阶段的视神经炎和多发性硬化症，导致改善视力障碍和功能缺陷与疾病的不同阶段遇到的单独的病理组合。神经元活力的测定和获得的相关治疗参数的知识将表明该方法治疗自身免疫性视神经炎的潜力，作为该项目的总体目标。这种治疗方法的自身免疫性视神经炎的重点是抑制中枢神经系统自身免疫反应，神经保护，轴突再生和髓鞘通过不同的机制。它具有预防和治疗的潜力，并补充现有的治疗设计和原理，解决自身免疫性视神经炎治疗的其他方面。